Skip to main
ANL

ANL Stock Forecast & Price Target

ANL Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adlai Nortye is building a promising pipeline of drug candidates with a focus on RAS-targeting therapies and next-generation cancer immunotherapies. With its differentiated approach of localizing panRAS inhibition and its competitive pre-clinical profile, coupled with the potential for intermittent dosing and combination therapy, AN9025 has the potential to become a best-in-class panRAS inhibitor and carve out a sizable market share in RAS-driven cancers. Furthermore, Adlai Nortye's modest valuation compared to its competitors and the potential for global deals and development partnerships add to the upside potential of this stock.

Bears say

Adlai Nortye is a clinical-stage company with a negative outlook, as its AN9025 panRAS inhibitor faces potential toxicity issues due to its higher affinity and longer half-life. The company has not yet generated revenue, making it dependent on the successful commercialization of its current candidates to achieve profitability. However, AN9025's potential intermittent dosing and AN4035's localized delivery are promising differentiators from other RAS-targeting therapies. Despite these potential advantages, the company's clinical validation, pipeline failures, and liquidity risk could delay its time to profitability.

ANL has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adlai Nortye Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adlai Nortye Ltd (ANL) Forecast

Analysts have given ANL a Strong Buy based on their latest research and market trends.

According to 3 analysts, ANL has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adlai Nortye Ltd (ANL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.